Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 2.5% - Should You Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) shares fell 2.5% during trading on Monday . The company traded as low as $33.20 and last traded at $34.60. 232,175 shares changed hands during mid-day trading, a decline of 76% from the average session volume of 957,680 shares. The stock had previously closed at $35.48.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Noble Financial reiterated an "outperform" rating and issued a $70.00 target price on shares of Tonix Pharmaceuticals in a research note on Thursday, March 20th. Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Finally, Alliance Global Partners reiterated a "buy" rating on shares of Tonix Pharmaceuticals in a research note on Tuesday, June 3rd.

Tonix Pharmaceuticals Stock Up 10.4%

The firm's fifty day moving average price is $32.16 and its two-hundred day moving average price is $24.58. The stock has a market capitalization of $311.77 million, a PE ratio of -0.02 and a beta of 2.05.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($2.84) earnings per share for the quarter, beating the consensus estimate of ($3.23) by $0.39. Tonix Pharmaceuticals had a negative net margin of 1,313.87% and a negative return on equity of 120.96%. The firm had revenue of $2.43 million during the quarter, compared to analysts' expectations of $2.55 million. As a group, analysts predict that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current year.

Insider Buying and Selling at Tonix Pharmaceuticals

In related news, CEO Seth Lederman acquired 4,000 shares of the firm's stock in a transaction dated Thursday, May 15th. The stock was purchased at an average cost of $21.55 per share, with a total value of $86,200.00. Following the completion of the acquisition, the chief executive officer directly owned 4,005 shares of the company's stock, valued at approximately $86,307.75. This trade represents a 80,000.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.03% of the stock is owned by insiders.

Institutional Trading of Tonix Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its holdings in Tonix Pharmaceuticals by 1,600.1% during the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company's stock valued at $650,000 after buying an additional 1,855,907 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in Tonix Pharmaceuticals during the fourth quarter valued at approximately $526,000. Two Sigma Investments LP purchased a new stake in Tonix Pharmaceuticals during the fourth quarter valued at approximately $66,000. Jane Street Group LLC increased its holdings in Tonix Pharmaceuticals by 5,932.3% during the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company's stock valued at $548,000 after buying an additional 1,635,119 shares during the last quarter. Finally, Northern Trust Corp purchased a new stake in Tonix Pharmaceuticals during the fourth quarter valued at approximately $162,000. 82.26% of the stock is owned by hedge funds and other institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.